Vesting of Options under Long-Term Incentive Plan

AI SummaryClose X

Allergy Therapeutics plc announced the outcome of its Long-Term Incentive Plan, with 30% of awards vesting due to achieved regulatory performance targets, while 70% lapsed as EBITDA targets were not met. A total of 7,671,078 share options vested at an exercise price of £0.001 per share, with 4,038,054 of these vested options held by PDMRs Manuel Llobet and Shaun Furlong. The share price threshold was met, but the EBITDA performance conditions were not achieved.

Disclaimer*

UK 100

Latest directors dealings